A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
Public ClinicalTrials.gov record NCT00751231. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12 Inhibitor, vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing Non-Urgent PCI
Study identification
- NCT ID
- NCT00751231
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Enrollment
- 652 participants
Conditions and interventions
Conditions
Interventions
- clopidogrel Drug
- PRT060128 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2008
- Primary completion
- Mar 31, 2010
- Completion
- Mar 31, 2010
- Last update posted
- Aug 7, 2023
2008 – 2010
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Portola Investigational Site | La Jolla | California | — | — |
| Portola Investigational Site | Torrance | California | — | — |
| Portola Investigational Site | Washington D.C. | District of Columbia | — | — |
| Portola Investigational Site | Jacksonville | Florida | — | — |
| Portola Investigational Site | Tallahassee | Florida | — | — |
| Portola Investigational Site | Augusta | Georgia | — | — |
| Portola Investigational Site | Lexington | Kentucky | — | — |
| Portola Investigational Site | New Orleans | Louisiana | — | — |
| Portola Investigational Site | Portland | Maine | — | — |
| Portola Investigational Site | Baltimore | Maryland | — | — |
| Portola Investigational Site | Detroit | Michigan | — | — |
| Portola Investigational Site | Grand Blanc | Michigan | — | — |
| Portola Investigational Site | Brooklyn | New York | — | — |
| Portola Investigational Site | Charleston | North Carolina | — | — |
| Portola Investigational Site | Winston-Salem | North Carolina | — | — |
| Portola Investigational Site | Cincinnati | Ohio | — | — |
| Portola Investigational Site | Hershey | Pennsylvania | — | — |
| Portola Investigational Site | Lancaster | Pennsylvania | — | — |
| Portola Investigational Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00751231, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 7, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00751231 live on ClinicalTrials.gov.